Obsidian Therapeutics to focus on the advancement of its pipeline of novel engineered TIL cell therapies for the treatment of patients with solid tumors Post-transaction cash and cash equivalents of approximately $350 million expected to fund operations into 2H 2028, including NSCLC Phase 1 data expected in 1H 2027 and melanoma registration-enabling data expected year-end 2027 Shares to begin trading on Nasdaq under ticker symbol “OBX” on August 4, 2026 Obsidian Therapeutics, Inc. (“Obsidian”)

Just days after completing a $10.6bn takeover of lung cancer biotech Nuvalent, GSK is already reaping the rewards with Jideytro (zidesamtinib) having gained US approval in ROS1-positive non-small cell lung cancer (NSCLC). This means the selective ROS1 kinase inhibitor is now indicated for use in American adults with locally advanced or metastatic ROS1-positive NSCLC, provided they have already previously received treatment with a prior ROS1 kinase inhibitor. This is GSK’s first drug for lung ca

Longtime investor OPKO Health increases its position as Cocrystal advances toward norovirus Phase 1b data in late 2026 Aug. 03, 2026 -- Cocrystal Pharma, Inc. (Nasdaq: COCP) ("Cocrystal" or the "Company"), a biotechnology company developing novel antiviral therapeutics, today announced a $5 million investment from OPKO Health, Inc. (Nasdaq: OPK) (“OPKO”), a longtime investor in the Company, has increased its position through a $5 million investment as the Company advances its lead norovirus pro

Funding led by Guozhong Capital will accelerate Phase 2 development for saRNA candidate RAG-01 and CNS asset RAG-17, advance systemic saRNA program RAG-18 toward IND, and expand extrahepatic RNA delivery technologies. July 29, 2026 -- Ractigen Therapeutics, a clinical-stage biotechnology company pioneering small activating RNA (saRNA) therapeutics and advanced extrahepatic delivery systems, today announced the successful closing of a new financing round exceeding $31 million (over RMB 200 milli

Ad hoc announcement pursuant to Art. 53 LR July 29, 2026 Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial and fungal infections, announced today that the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response (ASPR) within the U.S. Department of Health and Human Services (HHS), awarded USD 30 million in additio

Led by Lotus Lake Capital, the financing will accelerate the development of TPM004, a differentiated ultra-long-acting amylin/calcitonin receptor dual agonist, and advance the company's proprietary PepTetris™ peptide discovery platform for obesity, diabetes, and other metabolic diseases Developing a differentiated portfolio of ultra-long-acting peptide therapeutics targeting metabolic diseases, including obesity, type 2 diabetes, and related disorders, with the potential to achieve best-in-clas

The venture financing and AMED grant funding position CORE to accelerate development of novel lineage-based oncology therapies for patients around the world. July 28, 2026 -- CORE Biomedicine, a biotechnology company pioneering lineage-based precision oncology therapeutics, today announced the completion of a $21 million Series A financing. The round is co-led by UTokyo Innovation Platform Co., Ltd. and Elikon Venture, alongside participation from InnoPinnacle Fund, Mitsubishi UFJ Capital Co.,

Proceeds to support ongoing late-stage global clinical development and commercialization preparation of dotinurad, a next-generation, once daily, oral URAT1 inhibitor with the potential to deliver best-in-class safety and efficacy for the treatment of gout July 27, 2026 -- Urica Therapeutics, Inc. (“Urica” or the “Company”), a Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress”) subsidiary, today announced that Crystalys Therapeutics, Inc. (“Crystalys”), in which Urica maintains an equity positio

Scribe Therapeutics has overshot its own expectations with an IPO that's set to bring in $128.7 million for the in vivo gene editing outfit. Scribe is issuing 8.6 million shares—above the 7.1 million shares that the company had suggested on Monday . At $15 apiece, the biotech has also priced the shares, which will list on the Nasdaq today under the ticker “SCTX,” at the top end of the $13-15 range it had previously set out. It means the company expects to bring in $128.7 million in gross proce

US$4.6 million financing fully capitalizes N-Zyme Biomedical’s planned Phase 2 clinical programs in laryngopharyngeal reflux and PPI-refractory GERD, supporting the advancement of its first-in-class pepsin-targeted therapeutic approach. N-Zyme Biomedical today announced the successful closing of its Series A financing, raising approximately US$4.6 million to accelerate the advancement of its Phase 2 clinical programs and further the development of its novel pepsin inhibitor platform for refl